Marshall Wace, LLP Poseida Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 40,193 shares of PSTX stock, worth $110,932. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,193
Previous 10,538
281.41%
Holding current value
$110,932
Previous $30,000
280.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding PSTX
# of Institutions
97Shares Held
38.5MCall Options Held
377KPut Options Held
22.2K-
Pentwater Capital Management LP Naples, FL5.98MShares$16.5 Million0.18% of portfolio
-
Black Rock Inc. New York, NY4.91MShares$13.5 Million0.0% of portfolio
-
Silverarc Capital Management, LLC3.69MShares$10.2 Million2.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.66MShares$10.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.19MShares$6.05 Million0.0% of portfolio
About Poseida Therapeutics, Inc.
- Ticker PSTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 85,775,600
- Market Cap $237M
- Description
- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...